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ABSTRACT
The C-terminal domain (CTD) of mammalian RNA
polymeraseIIconsistsof52repeatsoftheconsensus
hepta-peptide YSPTSPS, and links transcription to
the processing of pre-mRNA. Although Pol II with a
CTD shortened to five repeats (Pol II D5) is transcrip-
tionallyinactiveonchromatintemplates,itisnotclear
whether CTD is required for promoter recognition
in vivo. Here, we demonstrate that in the context of
chromatin, Pol II D5 can bind to the c-myc promoter
with the same efficiency as wild type Pol II. However,
PolIID5doesnotformastableinitiationcomplex,and
does not transcribe promoter proximal sequences.
Fluorescence recovery after photobleaching (FRAP)
experiments with cells expressing enhanced green
fluorescent protein (EGFP)-tagged D5 or wildtype
PolIIrevealedasingle,highlymobilePolIID5fraction
whereas wildtype Pol II yielded less mobile fractions.
These data suggest that CTD is not required for pro-
moter recognition, but rather for subsequent forma-
tion of a stable initiation complex and isomerization
to an elongation competent complex.
INTRODUCTION
The large subunit of eukaryotic RNA polymerase II (Pol II LS)
harbours a unique C-terminal domain (CTD) consisting of
repeats of the consensus hepta-peptide sequence YSPTSPS
(1). The consensus sequence is highly conserved across organ-
isms, but the number of repeats appears to have increased
through evolution (2).
The phosphorylation status of the CTD is essential for the
regulation of transcription [reviewed in (3,4)]. In vivo,only the
non-phosphorylated (IIA) form of Pol II can participate in
the formation of a pre-initiation complex (PIC), while CTD
phosphorylation is essential for transcriptional elongation
(the IIO form) (3,4). The effectors of this regulation include
several cyclin-dependent-, and stress-activated kinases, whose
activities during certain stages of the transcription cycle may
serve to regulate initiation, elongation and the binding of pre-
mRNAprocessing factorstoPolII[for reviews see (5–8)]. The
phosphorylation of non-engaged Pol II by kinases, such as
ERK or CDK8/cyclin C may function to down regulate the
transcription by preventing the formation of new PICs (9–11),
suggesting that the CTD could be involved in controlling early
steps of initiation. Phosphorylation of Pol II during the trans-
ition from initiation to elongation by CDK7/cyclin H of the
general transcription factor TFIIH, and CDK9/cyclins T and K
of the elongation factor P-TEFb, may relieve the inhibitory
effects of the DSIF, NELF and Mediator complexes. Hence,
Pol II with phosphorylated CTD (Pol II0) has a speciﬁc defect
in the initiation on chromatin templates, while a polymerase
with an unphosphorylated CTD can properly initiate. This
leaves open the question whether an unphosphorylated CTD
is required for promoter recognition, or if a CTD-deleted Pol II
can recognize a chromatin-packaged promoter as well.
Here, we showthatthe recognitionofthec-mycpromoterby
Pol II with a CTD truncated to ﬁve repeats (Pol II D5) is not
affected in the context of chromatin, while subsequent steps
like stable PIC formation and isomerization to an elongation
competent complex are severely impaired. This is in agree-
ment with our further observation that Pol II D5 is highly
mobile in ﬂuorescence recovery after photobleaching
(FRAP) experiments and not stably associated with nuclear
structures.
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Cell culture and cell lines
Cell lines were obtained by stable transfection of the Burkitt’s
lymphoma cell line Raji with DNA encoding the 8.1 kb
HindIII–EcoRI c-myc gene locus on the episomal, self-
replicating Epstein–Barr virus (EBV)-derived vector KH375,
and selected with hygromycin. Subsequently, cells were trans-
fected with LSmock, Pol II wt or Pol II D5 carrying a tet-off
regulatable promoter (12), and selected with neomycin. HeLa
cells were transfected with the plasmid pSV40-H2B-mRFP1
and stable single cell clones expressing H2B-MRFP were
isolated. Positive cell clones were subsequently transfected
with plasmids expressing a-amanitin resistant fusions of the
large subunit of Pol II wt or Pol II D5 and enhanced green
ﬂuorescent protein (EGFP) (13) and selected with neomycin.
If indicated, cells were treated with ﬁnal concentrations of
2 mg/ml a-amanitin or 3 mM/ml sodium butyrate (SoB).
Nuclear run-on assay, S1 analysis
Isolation of nuclei, puriﬁcation and hybridization of labelled
RNA to membrane-bound oligonucleotides, the washing
procedure of membranes including the digestion of single-
stranded RNA with RNAse A, oligonucleotides complement-
ary to the human antisense c-myc strand, in vitro transcribed
T7 control RNA, as well as S1 analysis have been described in
detail elsewhere (14).
Chromatin immunoprecipitation (ChIP) analysis
Cells were formaldehyde cross-linked and immunoprecipit-
ated as described previously (14). Antibodies against HA-
tag (3F10, Roche) and isotype control (Santa Cruz) were
applied. Antibody/protein/DNA complexes were isolated by
immunoprecipitation with blocked protein A positive Staph A
cells. Following extensive washing, bound DNA fragments
were eluted and analysed by subsequent PCR. Each reaction
contained 3 ml of immunoprecipitated DNA, 1· Taq reac-
tion buffer (Promega), 1.5 mM MgCl2, 50 ng of each primer,
1.7 U Taq polymerase (Promega) and 200 mM each dNTP
(Boehringer Mannheim) (including 1 mCi [
32P]dCTP) in a
ﬁnal reaction volume of 20 ml. PCRs were ampliﬁed for
1cycleat95 Cfor5min,annealingtemperatureoftheprimers
for 5 min, 72 C for 3 min and 27 cycles at 95 C for 1 min,
annealing temperature of the primers for 2 min, 72 C for
1.5 min. PCR products were separated by electrophoresis
through a 6% polyacrylamide gel, and visualized by auto-
radiography. The following primers were used for the c-myc
promoter region and insulin gene:
Myc-1: 50-GGTCTGGACGGCTGAGGACCCCCG-30;
Myc-2: 50-CTCTCGCTGGAATTACTACAGCG30;
Insulin 1: 50-GCTGGTAGAGGGAGCAGATG-30;
Insulin 2: 50-CCCTGACTGTGTCCTCCTGT-30.
FRAP analysis
FRAP analysis was performed on HeLa cells expressing H2B-
MRFP, and Pol II wt-EGFP or Pol II D5-EGFP. Cells were
seeded on round coverslips ﬁtting in the temperature con-
trolled (37 C) POC-Chamber (LaCon, Germany). Live cell
microscopy was performed with a Zeiss LSM510 Meta con-
focal microscope equipped with 63·/1.4 NA Plan apochromat
oil objective. An Ar laser (488 nm, 35 mW) and a HeNe laser
(543 nm, 1 mW) were used to excite the ﬂuorescent proteins.
Image acquisition before and after bleaching was performed at
low laser power (5%). For FRAP analysis a region of interest
was selected and photobleached by an intense 488 nm Ar laser
beam (set to 100%) for 5 s, after which confocal image series
were recorded at 1 s time intervals for 1 min and thereafter at
5 s time intervals for  4 min. Mean ﬂuorescence intensities of
the bleached region were corrected for background and for
total nuclear loss of ﬂuorescence over the time course. FRAP
data of at least eight nuclei were averaged and the mean curve
as well as the standard deviations were plotted. As a control
ﬁxed specimen (4% paraformaldehyde, 10 min) of the same
cell lines mounted in Vectashield (Vector, USA) were subjec-
ted to FRAP analysis and plotted as well.
RESULTS AND DISCUSSION
CTD is not required for recognition and binding to
the c-myc promoter in vivo
A requirement for the CTD in the control of promoter escape
and maturation of mRNA in vivo has been documented in
detail before. Its role in promoter recognition, formation of
a stable initiation complex and isomerization to an elongation
competent complex, however, is still elusive. The c-myc pro-
moter is an ideal tool to study this question, since Pol II is
stalled immediately after the isomerization step proximal to
the promoter. At this position Pol II is easily detectable in run-
on transcription assays.
We have previously reconstituted transcriptional regulation
of the c-myc gene on stably transfected episomal vectors in the
B cell line, Raji. The episomal c-myc establishes a chromatin
structure undistinguishable from the structure of an endogen-
ous c-myc to the nucleosomes positioned upstream and down-
stream of the c-myc promoter. Importantly, episomes carry a
stalled Pol II immediately downstream of the major c-myc P2
promoter as it is observed for the endogenous c-myc (14–18).
We used Raji cells with a reconstituted c-myc chromatin on
episome KH375 (Figure 1A), and introduced an additional
episome carrying a tetracycline-regulatable, a-amanitin res-
istant large subunit of Pol II into these cells (Figure 1B). Cell
lines were established carrying only the vector (mock), Pol II
with the complete CTD (Pol II wt), or with internal deletions
of 21 (Pol II D31; deletion of 23–36 + 39–47) and 47 repeats
(Pol II D5; deletion of 4–50) (12,19). The copy number of
episomes as determined by Southern analysis turned out to be
similar for the c-myc and Pol II constructs in all cell lines
(Figure 1C). Similar levels of the large subunit of Pol II
were induced in all cell lines after removal of tetracycline
(Figure 1D). Pol II wt and Pol II D31 displayed both the
hyperphosphorylated (Pol II0) and hypophosphorylated
(Pol IIa) forms while Pol II D5 migrated as a single small
band in gel electrophoresis. Pol II D31 behaved like Pol II
wt and is not further shown in the following experiments.
ChIPexperimentswereperformedtomeasurethebindingof
the Pol II wt and Pol II D5 to the c-myc promoter. Both RNA
polymerases cross-linked to the c-myc promoter with the same
highefﬁciency(Figure 1E, lanes 3and 11). Nocross-linking to
the c-myc promoter could be observed in the mock cell line
(lane 7), or to the promoter of the insulin gene, which is not
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linking of E2F to the c-myc promoter (14) was seen in all
cell lines and is therefore not affected by the expression of
Pol II wt, and Pol II D5 (data not shown). We conclude that
Pol II D5 binds and cross-links to the c-myc promoter with
the same efﬁciency as Pol II wt, and that the CTD has neither
a positive or negative effect on c-myc promoter recognition.
Whether the hypo- and hyperphosphorylated Pol II0 can
recognize the c-myc promoter with different efﬁciencies, as
reported previously for the adenovirus major late promoter
(20), cannot be analysed in this assay, and remains unclear.
CTD is required for stable PIC formation and/or
isomerization of Pol II at the c-myc promoter
The episomal c-myc is induced after inhibition of histone
deacetylase (HDAC) activity (14). We next tested whether
Pol II wt and Pol II D5 can transcribe the c-myc gene after
inhibition of HDAC activity by SoB. Cells were induced by
removal of tetracycline, and treated with a-amanitin and SoB
asindicated inFigure2A.Expressionoftheepisomalc-myc by
SoB is induced in Pol II wt cells (Figure 2B, lane 9) but not in
Mock and Pol II D5 cells (lanes 1 and 5). Note that transcrip-
tion of the translocated, Ig-enhancer driven c-myc gene is
repressed by SoB in Raji cells, leaving the signal for c-myc
mRNA in lane 9 unchanged (14). However, induction of the
episomal and repression of the translocated c-myc is distin-
guishablebyS1analysis. P1tandP2tmRNAsarederived from
the translocated c-myc (lane 14) and P2 mRNA is derived from
the episomal c-myc (lane 13).
Importantly, the failure of Pol II D5 to induce c-myc expres-
sion is not solely caused by its inability to support maturation
of c-myc mRNA. Nuclear run-on experiments showed that Pol
II D5 is defective in the initiation of transcription at the c-myc
promoter and cannot transcribe promoter proximal sequences
(Figure 2C, lane 2). In contrast, transcription by Pol II wt
produced strong transcription signals on oligonucleotides E,
F and G downstream of the c-myc P2 promoter (Figure 2C,
lane 4). These signals were not detectable for Pol II D5 and
mock cells (lanes 2 and 3). Since pausing of Pol II at the
translocated c-myc promoter is abolished in Burkitt’s lymph-
oma cells (21), including Raji cells (22), the detected run-on
signals are almost derived exclusively from episomal c-myc
alleles. From these data we conclude that Pol II D5 is defective
Figure 1. EfficientbindingofPolIID5tothec-mycpromoter.(A)Rajicelllinescarryingtheepisomalc-mycgenelocus,andinaddition(B)eitherLS*Mock(vector
control),PolIIwt,orPolIID5wereestablished.(C)ThecopynumberofconstructswasdeterminedbySouthernanalysiswithspecificprobesfortheneomycinand
hygromycin resistance genes. 1·,1 0 · and 100· correspond to 1, 10 and 100 copies/genome, respectively. (D) Proper expression of Pol II wt and Pol II D5 after
removal of tetracycline was controlled by western blot analysis using anti-HA antibodies. Pol II D31 served as size control. (E) ChIP analysis revealed similar
binding of Pol II D5 and Pol II wt to the c-myc promoter (lanes 3 and 11, respectively), while binding was not detectable in the Mock cell line (lane 7), or (F)t oa
non-transcribed region in the insulin gene.
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the subsequent isomerization step to an elongation competent
complex. The strong cross-linking of Pol II D5 to the c-myc
promoter argues that Pol II D5 is present at the c-myc promoter
at least as frequently as Pol II wt, but is defective in initiating
transcription.
Nuclear mobility of EGFP-tagged Pol II wt
versus -Pol II D5
To study the nuclear mobility of Pol II wt and Pol II D5i n
living cells, we fused EGFP to the carboxy-terminus of both
molecules (Figure 3A), and expressed them under the control
ofthethymidine-kinase promoterinHeLa cells stably express-
ing a histone 2B-MRFP. HeLa cells expressing Pol II
wt-EGFP turned out to be viable and could be cultured and
expanded for months in the presence of a-amanitin. In con-
trast, Pol II D5-EGFP expressing cells could be cultured in the
presence of a-amanitin for only three days before signiﬁcant
cell death was observed. Therefore, cells were selected with
neomycin for 10 days before a-amanitin was added and FRAP
experiments were performed. Cloning of EGFP to the
carboxy-terminus of the large subunit of Pol II wt and Pol II
D5 resulted in stable fusion proteins. Importantly, the stability
of CTD is controlled by repeats 1–3 and repeat 52 (last repeat)
in vivo (13,23). These repeats are present in Pol II D5. More-
over, we could recently show that fusion of EGFP to the
C-terminus of Pol II mutants lacking repeats 1–3 and repeat
52 fully rescued the stability of CTD deletion mutants (23).
Both Pol II wt-EGFP and Pol II D5-EGFP displayed nuclear
staining with the exclusion of the nucleoli (Figure 3B, panel 2
and 3). In Figure 3B panel 1 is an example of the EGFP signal
of a ﬁxed HeLa H2B-mRFP nucleus, stably transfected with
Pol II wt-EGFP. Bleaching a region of interest results in a loss
of EGFP ﬂuorescence and an imprinted hole, observable over
the whole time course and serving as a positive control for an
effective bleaching event. Panel 4 in Figure 3B is an example
of an monomeric red ﬂuorescent protein (MRFP) signal of
unﬁxed HeLa H2B-MRFP, Pol II D5-EGFP cells. Similar to
the ﬁxed cells, the MRFP signal shows only little recovery
duringthe350sobservationtime.Themeanintensitiesofsuch
a bleached region calculated over the whole observation are
plotted in Figure 3C. In case of the ﬁxed control a loss of ﬂuor-
escenceto 30%isobserved(Figure3C,bluecurve).Thesame
result was obtained when performing FRAP analysis on ﬁxed
cells stably transfected withPol II D5-EGFP (data not shown).
FRAP analysis performed on living HeLa cells expressing
Pol II wt-EGFP (exemplary nucleus shown in Figure 3B, panel
2) reveals a recovery curve reaching a plateau after  200 s
(Figure 3C, green curve). The recovery behaviour of Pol II
wt-EGFP is in accordance with data reporting several popu-
lations of Pol II with differing kinetics (24,25). At least three
populations of Pol II exist, based on their differing kinetics.
The largest fraction ought to be a free diffusing pool enabling
the rapid recovery observable over the ﬁrst 50 s. The other two
fractions ought to be either bound but inactive, or bound and
elongating polymerase-II-GFP molecules, which recover
much slower and lead to the slightly accelerated recovery
in the subsequent observation.
In contrast, performing FRAP analysis on HeLa cells stably
expressing Pol II D5-EGFP (exemplary nucleus shown in
Figure 3B, panel 3) reveals a much faster recovery
(Figure 3C, red curve). This argues for a high take off rate,
and an increase of the free diffusing population of Pol II D5
correlating with the loss of 47/52 repeats of the CTD. We note
that the bulk dynamics observed for the different polymerases
may not reﬂect the situation at particular loci.
CONCLUSIONS
The ﬁnding that CTD is dispensable for the recognition of the
c-myc promoter in the context of chromatin, but required for
Figure 2. Transcription of the c-myc promoter by recombinant Pol II. (A)
Tetracyclinewaswashedoutfromcelllinesattimepoint0htoallowexpression
of Pol II wt and Pol II D5. a-amanitin was added 24 h later to achieve quanti-
tative inhibition of the endogenous Pol II. After 16 h, transcription of the
episomal c-myc was induced by treatment of cells with SoB for 14 h.
(B) northern analysis of c-myc RNA (left hand site), discrimination of endo-
genousandepisomalc-mycRNAbyS1analysis(righthandsite).P1t/P2tmark
RNAfromtheendogenous,translocatedc-mycgene(lane14),P1/P2RNAfrom
theepisomalc-myc(lane13).(C)Nuclearrun-onactivityofPolIID5andPolII
wt at the episomal c-myc promoter. Cells were treated as described in (A), but
nuclei were isolated 24 h after addition of a-amanitin, cells were not induced
with SoB. (A–J) Long antisense oligonucleotides (50 nt) covering the c-myc
promoter region; 7SK: antisense oligonucleotide for Pol III transcribed 7SK
gene; T7: T7 RNA polymerase transcribed, uniformely labelled RNA of the
c-myc promoter region.
5142 Nucleic Acids Research, 2005, Vol. 33, No. 16Figure3.FRAPanalysisofEGFP-taggedPolII.(A)PolIIwtandPolIID5weretaggedwithEGFPatthecarboxy-terminus.(B)PolII-EGFPandH2B-MRFPsignals
of exemplary nuclei subjected to FRAP analysis were shown: fixed Pol II wt-EGFP (panel 1); live Pol II wt-EGFP (panel 2), live Pol II D5-EGFP (panel 3) and
liveH2B-MRFP(panel4).Theimagesshowthesignaldistributionbefore(‘Prebleach’),rightafterthebleaching(‘Postbleach’)andafterarecoveryperiodof150and
350 s. The squares in the Prebleach images indicate the bleached region of interest. (C) The plotted curves represent the mean relative intensities measured in the
bleached regions over time. The averaged values of 4, 10, 8 and 6 nuclei (fixed Pol II wt-EGFP, live Pol II wt-EGFP, live Pol II D5-EGFP and live H2B-MRFP,
respectively) andaccordingly the standarddeviationswere plottedforeach time point.Fixedsamplesservedaspositivecontrolsand confirmedthe effectiveness of
the bleaching indicated by a drastic drop of the curve to  30% and a subsequent stay at this level (blue curve).
Nucleic Acids Research, 2005, Vol. 33, No. 16 5143the isomerization of Pol II into an elongating enzyme under-
scores our notion that CTD is not only important for the con-
trol of RNA elongation, but also for the process of initiation.
For this step, the CTD of Pol II probably exist must in its
hypophosphorylated form. The inability of a CTD-deleted
polymerase to initiate and to transcribe to promoter proximal
pause sites may also be asafety mechanism.We could recently
show that the integrity of Pol II in vivo can be controlled by a
protease that cleaves the CTD from the large subunit (13,23).
Removal of the CTD would not only disconnect such poly-
merases from the CTD-associated RNA-processing
machinery, but also would prevent further rounds of transcrip-
tion by such polymerases.
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